Trial Profile
Targeting neutrophil extracellular traps with dornase alfa to reduce inflammation in chronic airway disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2020
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Acronyms NETs
- 16 Mar 2020 Planned number of patients changed from 100 to 30.
- 16 Mar 2020 Status changed from recruiting to completed.
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.